RU2005123802A - Производные адамантана, способы их получения и содержащие их фармацевтические композиции - Google Patents
Производные адамантана, способы их получения и содержащие их фармацевтические композиции Download PDFInfo
- Publication number
- RU2005123802A RU2005123802A RU2005123802/04A RU2005123802A RU2005123802A RU 2005123802 A RU2005123802 A RU 2005123802A RU 2005123802/04 A RU2005123802/04 A RU 2005123802/04A RU 2005123802 A RU2005123802 A RU 2005123802A RU 2005123802 A RU2005123802 A RU 2005123802A
- Authority
- RU
- Russia
- Prior art keywords
- tricyclo
- chloro
- dec
- formula
- ylmethyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 title 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 30
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 12
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 10
- -1 nitro, amino, hydroxyl Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000004889 1-methylethylamino group Chemical group CC(C)N* 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
- C07C13/605—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system
- C07C13/615—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system with an adamantane ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300480A SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Novel compounds |
| SE0300480-1 | 2003-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005123802A true RU2005123802A (ru) | 2006-02-27 |
Family
ID=20290476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005123802/04A RU2005123802A (ru) | 2003-02-21 | 2004-02-19 | Производные адамантана, способы их получения и содержащие их фармацевтические композиции |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7227038B2 (enExample) |
| EP (1) | EP1599432A1 (enExample) |
| JP (1) | JP2006518376A (enExample) |
| KR (1) | KR20050101559A (enExample) |
| CN (1) | CN100378047C (enExample) |
| AU (1) | AU2004213356B2 (enExample) |
| BR (1) | BRPI0407734A (enExample) |
| CA (1) | CA2515434A1 (enExample) |
| CO (1) | CO5580815A2 (enExample) |
| IL (1) | IL169818A0 (enExample) |
| IS (1) | IS8024A (enExample) |
| MX (1) | MXPA05008690A (enExample) |
| NO (1) | NO20054329L (enExample) |
| PL (1) | PL378574A1 (enExample) |
| RU (1) | RU2005123802A (enExample) |
| SE (1) | SE0300480D0 (enExample) |
| WO (1) | WO2004074224A1 (enExample) |
| ZA (1) | ZA200506579B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| WO2004105796A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| CA2526883A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha. |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| US8916546B2 (en) | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| ES2305887T3 (es) | 2003-12-18 | 2008-11-01 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos. |
| GB0403864D0 (en) | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
| WO2007008155A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 1 |
| WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
| EP2044084B1 (en) | 2006-07-13 | 2016-02-17 | Janssen Pharmaceutica NV | Mtki quinazoline derivatives |
| TW200819416A (en) * | 2006-09-05 | 2008-05-01 | Astrazeneca Ab | Novel process 470 |
| DK2185562T3 (en) | 2007-07-27 | 2016-02-22 | Janssen Pharmaceutica Nv | PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES |
| ES2357682T3 (es) | 2008-03-25 | 2011-04-28 | Affectis Pharmaceuticals Ag | Antagonistas de p2x7r novedosos y su utilización. |
| KR20100053150A (ko) * | 2008-11-12 | 2010-05-20 | 한국생명공학연구원 | 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물 |
| CN102395562A (zh) | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
| EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2013014587A1 (en) | 2011-07-22 | 2013-01-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| TWI576347B (zh) | 2012-01-20 | 2017-04-01 | 艾克泰聯製藥有限公司 | 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物 |
| EP2916818B1 (en) | 2012-11-09 | 2017-02-01 | Scidose LLC | Enema composition for treatment of ulcerative colitis having long term stability |
| PL2931717T3 (pl) | 2012-12-12 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Pochodne indolokarboksyamidu jako antagoniści receptora p2x7 |
| CN104854087B (zh) | 2012-12-18 | 2017-03-22 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物 |
| WO2014115078A1 (en) | 2013-01-22 | 2014-07-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3352912A (en) | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3471491A (en) | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| GB1274652A (en) | 1968-08-27 | 1972-05-17 | Lilly Industries Ltd | Adamantanyl-alkylamine derivatives and their preparation |
| IL53441A0 (en) | 1977-11-22 | 1978-01-31 | Teva Pharma | Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them |
| US4349552A (en) | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| US4751292A (en) | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| PL181782B1 (pl) | 1993-08-10 | 2001-09-28 | Black James Foundation | Nowe zwiazki i sposób wytwarzania nowych zwiazków PL |
| FR2761358B1 (fr) | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ZA988967B (en) | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| TR200102911T2 (tr) | 1999-04-09 | 2002-01-21 | Astrazeneca Ab | Adamantan türevleri. |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物 |
| JP4523273B2 (ja) | 2001-07-02 | 2010-08-11 | ナームローゼ・フエンノートチヤツプ・オルガノン | テトラヒドロキノリン誘導体 |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300445D0 (sv) | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
| CA2526883A1 (en) | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha. |
| WO2004105797A1 (en) | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| WO2004105796A1 (en) | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
-
2003
- 2003-02-21 SE SE0300480A patent/SE0300480D0/xx unknown
-
2004
- 2004-02-19 JP JP2006502807A patent/JP2006518376A/ja not_active Withdrawn
- 2004-02-19 RU RU2005123802/04A patent/RU2005123802A/ru not_active Application Discontinuation
- 2004-02-19 CA CA002515434A patent/CA2515434A1/en not_active Abandoned
- 2004-02-19 CN CNB2004800047676A patent/CN100378047C/zh not_active Expired - Fee Related
- 2004-02-19 AU AU2004213356A patent/AU2004213356B2/en not_active Ceased
- 2004-02-19 WO PCT/SE2004/000227 patent/WO2004074224A1/en not_active Ceased
- 2004-02-19 KR KR1020057015302A patent/KR20050101559A/ko not_active Withdrawn
- 2004-02-19 BR BRPI0407734-2A patent/BRPI0407734A/pt not_active IP Right Cessation
- 2004-02-19 EP EP04712798A patent/EP1599432A1/en not_active Withdrawn
- 2004-02-19 US US10/546,131 patent/US7227038B2/en not_active Expired - Fee Related
- 2004-02-19 MX MXPA05008690A patent/MXPA05008690A/es unknown
- 2004-02-19 PL PL378574A patent/PL378574A1/pl not_active Application Discontinuation
-
2005
- 2005-07-21 IL IL169818A patent/IL169818A0/en unknown
- 2005-08-02 CO CO05076011A patent/CO5580815A2/es not_active Application Discontinuation
- 2005-08-17 ZA ZA200506579A patent/ZA200506579B/en unknown
- 2005-09-14 IS IS8024A patent/IS8024A/is unknown
- 2005-09-20 NO NO20054329A patent/NO20054329L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL378574A1 (pl) | 2006-05-02 |
| AU2004213356B2 (en) | 2007-03-15 |
| MXPA05008690A (es) | 2005-10-05 |
| KR20050101559A (ko) | 2005-10-24 |
| SE0300480D0 (sv) | 2003-02-21 |
| IS8024A (is) | 2005-09-14 |
| ZA200506579B (en) | 2006-05-31 |
| CA2515434A1 (en) | 2004-09-02 |
| US20060160904A1 (en) | 2006-07-20 |
| AU2004213356A1 (en) | 2004-09-02 |
| NO20054329L (no) | 2005-11-21 |
| CO5580815A2 (es) | 2005-11-30 |
| EP1599432A1 (en) | 2005-11-30 |
| US7227038B2 (en) | 2007-06-05 |
| NO20054329D0 (no) | 2005-09-20 |
| CN1751010A (zh) | 2006-03-22 |
| JP2006518376A (ja) | 2006-08-10 |
| CN100378047C (zh) | 2008-04-02 |
| IL169818A0 (en) | 2007-07-04 |
| BRPI0407734A (pt) | 2006-02-14 |
| WO2004074224A1 (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005123802A (ru) | Производные адамантана, способы их получения и содержащие их фармацевтические композиции | |
| JP2004524308A5 (enExample) | ||
| ES2315425T3 (es) | Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos. | |
| JP6306602B2 (ja) | 分子内環化−脱離による制御されたｈｎｏ放出 | |
| JP2006501295A5 (enExample) | ||
| RU2003120798A (ru) | Новые производные n-(фенилсульфонил) глицина и их применение в терапии | |
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| AU2014340182A1 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
| JP6270848B2 (ja) | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 | |
| JP2005524605A5 (enExample) | ||
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| CN110169962B (zh) | 用于治疗癌症的氧烯洛尔组合物 | |
| JP2017513824A5 (enExample) | ||
| JP2015531376A5 (enExample) | ||
| JPH0920659A5 (enExample) | ||
| JP2005015434A (ja) | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 | |
| CN1553890A (zh) | 羟基去甲麻黄素衍生物的各种结晶体型 | |
| WO2012074069A1 (ja) | 新規化合物及びその医薬用途 | |
| RU2005106355A (ru) | Новое соединение | |
| RU2002118700A (ru) | Замещенные производные норборниламина, способ их получения, их применение в качестве медикаментов или диагностических средств, а также содержащие их медикаменты | |
| RU2007107935A (ru) | Полисульфатированные гликозиды и их соли | |
| RU2011101661A (ru) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний | |
| JPH01128962A (ja) | 抗新生物剤としてのポリアミン誘導体類 | |
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы | |
| CN110612286A (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080416 |